Other

Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Japan As Represented by President of National Cancer Center

Asahi Kasei Medical Co., Ltd.

Med-tech Inc.

Yoko Kato

Hideharu Anazawa

Keiichi Yano

Seiji Sugimoto

Tadashi Nagashima

Tadanori Yamamura

Satoshi Kuroyanagi

Hiroyuki Ishida

Motoo Yamasaki

Kenya Shitara

Shiro Akinaga

Emi Hosaka

Akiko Furuya

Atsushi Ochiai

Kazuhisa Uchida

Tatsuya Tamaoki

Yukimasa Shiotsu

Toshio Ota

So Ohta

Haruhiko Yokoi

Yuka Sasaki

Liang Zhang

Kinya Yamashita

Norihiko Shiraishi

Noboru Konishi

Taisuke Nakata

Susume Sekine

Masato Kawashima

The present invention provides an antibody which specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by PERP (p53 apoptosis effector related to PMP-22) gene and binds to the extracellular region. The antibody of the present invention is useful for treatment of various diseases which highly expresses a polypeptide encoded by the PERP gene. Also, a polypeptide encoded by the PERP gene or a cell expressing the polypeptide can be specifically detected by an immunological method using the antibody, so that the antibody is useful for diagnosis of various diseases related to PERP.

Anti-perp antibody

The present invention relates to a fusion polypeptide which comprises a polypeptide having G-CSF activity and a polypeptide having TPO activity and DNA which codes for the fusion polypeptide, to a fusion polypeptide in which a polypeptide having G-CSF activity and a polypeptide having TPO activity are fused via a spacer peptide and DNA which codes for the fusion polypeptide and to a polypeptide in which the fusion polypeptide comprising a polypeptide having G-CSF activity and a polypeptide having TPO activity is chemically modified with a polyalkylene glycol derivative. It also relates to an anemia-treating composition containing the fusion polypeptide as an active ingredient.

hG-CSF fusion polypeptide having c-mpl activity, DNA coding for same and methods of treating anemia using same

The present invention provides a method of efficiently screening for steroid sulfatase activity-inhibiting compounds which are useful for the treatment of hormone-dependent diseases such as breast cancer, etc. by causing a test compound to act on cells carrying an introduced steroid sulfatase gene and estimating the inhibiting activity of the compound on the growth of the cells.

Method for searching steroid sulfatase inhibitors

Provided is an isolated phytase derived from a microorganism. The microorganism is preferably from the genus Monascus. The phytase has a Michaelis constant of 10 to 110 &mgr;M when phytic acid is used as a substrate. A process for producing the phytase is also provided as is an animal feed comprising the phytase. The phytase is preferably isolated from IFO 30873. The phytase has a Km of 107 &mgr;m when phytic acid is used as a substrate, the optimum pH is 2.5, the optimum temperature is 45&deg; C., the molecular weight of the phytase is 140 kDa when measured by gel filtration, and the isolectric point is 5.2 using chromatofocusing.

Phytase having a low Michaelis constant for phytic acid from monascus

The phytase is preferably isolated from IFO 30873. The phytase has a Km of 20 &mgr;m when phytic acid is used as a substrate, the optimum pH is 6.0, the optimum temperature is 50&deg; C., the molecular weight of the phytase is 120 kDa when measured by gel filtration, and the isolectric point is 4.8 using chromatofocusing.

Phytase having a low michaelis constant for phytic acid from monascus

Provided is an isolated phytase derived from a microorganism. The microorganism is preferably from the genus Monascus. The phytase has a Michaelis constant of 10 to 110 &mgr;M when phytic acid is used as a substrate. A process for producing the phytase also is provided, as is an animal feed comprising the phytase.

Growing community of inventors

Tokyo, Japan

Yoko Kato